Skip to main content
Log in

Autocrine and paracrine growth inhibitors of breast cancer cells

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Breast epithelial cells produce both mitogens and growth inhibitors which are involved in the control of mammary gland development through autocrine and paracrine pathways. While the mechanisms of action of several growth factors have been well established and related strategies proposed for breast cancer therapy, little is known concerning growth inhibitors. In this review, we present an overview of current information about major autocrine and paracrine growth inhibitors of breast epithelial cells, and we discuss their potential functions in the control of breast cancer development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Böehmer FD, Kraft R, Otto A, Wernstedt C, Hellmann U, Kurtz A, Mueller T, Rohde K, Etzold G, Lehmann W, Langen P, Heldin CH, Grosse R: Identification of a polypeptide growth inhibitor from bovine mammary gland. J Biol Chem 262: 15137–15143, 1987

    Google Scholar 

  2. Lehmann W, Widmaire R, Langen P: Response of different epithelial cell lines to a mammary derived growth inhibitor (MDGI): Biomed Biochim Acta 48: 143–151, 1989

    Google Scholar 

  3. Spener F, Unterberg C, Borchers T, Grosse R: Characteristics of fatty acid-binding proteins and their relation to mammaryderived growth inhibitor. Mol Cell Biochem 98: 57–68, 1990

    Google Scholar 

  4. Specht B, Bartetzko N, Hohoff C, Kuhl H, Franke R, Börchers T, Spener F: Mammary derived growth inhibitor is not a distinct protein but a mix of heart-type and adipocyte-type fatty acid-binding protein. J Biol Chem 271: 19943–19949, 1996

    Google Scholar 

  5. Börchers T, Hohoff C, Buhlmann C, Spener F: Heart-type fatty acid binding protein-involvement in growth inhibition and differentiation. Prostagalndins Leukot Essent Fatty Acids 57: 77–84, 1997

    Google Scholar 

  6. Yang Y, Spitzer E, Kenney N, Zschiesche W, Li M, Kromminga A, Muller T, Spener F, Lezius A, Veerkamp J, Smith G, Salomon D, Grosse R: Members of the fatty acid binding protein family are differentiation factors for the mammary gland. J Cell Biol 124: 1097–1109, 1994

    Google Scholar 

  7. Huynh H, Larsson C, Narod S, Pollak M: Tumour supressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res 55: 2225–2231, 1995

    Google Scholar 

  8. Huynh H, Alpert L, Pollak M: Silencing of mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res 56: 4865–4870, 1996

    Google Scholar 

  9. Massague J: TGF-beta signal transduction. Annu Rev Biochem 67: 753–791, 1998

    Google Scholar 

  10. Silberstein GB, Flanders KC, Roberts AB, Daniel CW: Regulation of mammary morphogenesis: Evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-beta 1. Dev Biol 152: 354–362, 1992

    Google Scholar 

  11. Pierce DJ, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, Daniel CW, Hogan BL, Moses HL: Inhibition of mammary duct development but not alveolar out-growth during pregnancy in transgenic mouse expressing active TGFb1. Genes Dev 7: 2308–2317, 1993

    Google Scholar 

  12. Strange R, Li F, Saurer S, Burkhardt A, Friis RR: Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 115: 49–58, 1992

    Google Scholar 

  13. Valverius EM, Walker-Jones D, Bates SE, StampferMR, Clark R, Mc Cormick F, Dickson RB, Lippman ME: Production of and responsiveness to transforming growth factor-b in normal and oncogene-transformed human mammary epithelial cells. Cancer Res 49: 6269–6274, 1989

    Google Scholar 

  14. Arteaga CL, Randon AK, Von Hoff DD, Osborne CK: Transforming growth factor-b: potencial autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48: 3898–3904, 1988

    Google Scholar 

  15. Zugmaler G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB: Transforming growth factor type b1 and b2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 141: 353–361, 1989

    Google Scholar 

  16. Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGFb type II receptor, a functional transmembrane serine/threonine kinase. Cell 68: 775–785, 1992

    Google Scholar 

  17. Kalkhoven E, Roelen BAJ, De Winter JP, Mummery CL, Van Den Eijnden-van Raaij AJM, Van Der Saag PT, Van Der Burg B: Resistance to transforming growth factor b and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 6: 1151–1161, 1995

    Google Scholar 

  18. Sun L, Chen C: Expression of transforming growth factor b type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem 272: 25367–25372, 1997

    Google Scholar 

  19. Chen C, Wang XF, Sun L: Expression of transforming growth factor-b (TGFb) type III receptor restores autocrine TGFb1 activity in human breast cancer MCF-7 cells. J Biol Chem 272: 12862–12867, 1997

    Google Scholar 

  20. De Winter JP, Roelen B, Ten Dijke P, Van Der burg B, Van Den Eijnden-Van Raaij A: DPC4 (SMAD4) mediates transforming growth factor-b1 (TGF-b1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 14: 1891–1899, 1997

    Google Scholar 

  21. Gorsch SM, Memoli VA, Stukel TA, Gold L, Arrick BA: Immunohistochemical staining for transforming growth factor-b1 associates with disease progression in human breast cancer. Cancer Res 52: 6949–6952, 1992

    Google Scholar 

  22. Chua CC, Geiman DE, Keller GH, Ladda RL: Induction of collagenase secretion in human fibroblast cultures by growth promoting factors. J Biol Chem 260: 5213–5216, 1985

    Google Scholar 

  23. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348: 699–704, 1990

    Google Scholar 

  24. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P: Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90: 1843–1847, 1993

    Google Scholar 

  25. Welch DR, Fabra A, Nakajima M: Transforming growth factor b stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87: 7678–7682, 1990

    Google Scholar 

  26. Dong-Le Bourhis X, Lambrecht V, Boilly B: Transforming growth factor-beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells. Br J Cancer 77: 396–403, 1998

    Google Scholar 

  27. Larrick JW, Wright SC: Cytotoxic mechanism of tumor necrosis factor-a. FASEB J 4: 3215–3223, 1990

    Google Scholar 

  28. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, LesslauerW, Loetscher H: Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87: 3127–3131, 1990

    Google Scholar 

  29. Varela LM, Ip MM: Tumor necrosis factor-a: A multifunctional regulator of mammary gland development. Endocrinology 137: 4915–4924, 1996

    Google Scholar 

  30. Dollbaum C, Creasey AA, Dairkee SH, Hiller AJ, Rudolph AR, Lin L, Vitt C, Smith HS: Specificity of tumor necrosis factor toxity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin. Proc Natl Acad Sci USA 85: 4740–4744, 1988

    Google Scholar 

  31. Jeoung D, Tang B, Sonenberg M: Effects of tumor necrosis factor-a on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J Biol Chem 270: 18367–18373, 1995

    Google Scholar 

  32. Liston P, Young SS, Mackenzie AE, Korneluk RG: Life and death decisions: the role of the IAPs in modulating programmed cell death. Apoptosis 2: 423–441, 1997

    Google Scholar 

  33. Basolo F, Conaldi PG, Fiore L, Calvo S, Toniolo A: Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma. Int J Cancer 55: 926–930, 1993

    Google Scholar 

  34. Green AR, Green VR, White MC, Speirs V: Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72: 937–941, 1997

    Google Scholar 

  35. Serve H, Oelmann E, Herweg A, Oberberg D, Serve S, Reufi B, Mucke C, Minty A, Thiel E, Berdel WE: Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res 56: 3583–3588, 1996

    Google Scholar 

  36. Gooch JL, Lee AV, Yee D: Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 58: 4199–4205, 1998

    Google Scholar 

  37. Chiu JJ, Kgagias MK, Cowan KH: Interleukin-6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 2: 215–221, 1996

    Google Scholar 

  38. Faggioli L, Costanzo C, Merola M, Bianchini E, Furia A, Carsana A, Palmieri M: Nuclear factor kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line. Eur J Biochem 239: 624–631, 1996

    Google Scholar 

  39. Haverty AA, Harmey JH, Redmond HP, Bouchier-Hayes DJ: Interleukin-6 upregulates GP96 expression in breast cancer. J Surg Res 69: 145–149, 1997

    Google Scholar 

  40. Figueroa JA, Yec D: The insulin-like growth factor binding proteins (IGFB Ps) in human breast cancer. Breast Cancer Res Treat 22: 381–390, 1992

    Google Scholar 

  41. Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M, Papas T, Seth A: Down-regulation of TlAl2/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 16: 2459–2467, 1998

    Google Scholar 

  42. Baxter RC, Martin JL: Binding proteins for insulin-like growth factors: Structure, regulation, and function. Prog Growth Factor Res 1: 49–56, 1989

    Google Scholar 

  43. Nickerson T, Huynh H, Pollak M: Insulin-like growth factor binding protein-3 induces apoptosis in MCF-7 breast cancer cells. Biochem Biophys Res Commun 237: 690–693, 1997

    Google Scholar 

  44. Mohseni-Zadeh S, Binoux M: Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action. Endocrinology 138: 5645–5648, 1997

    Google Scholar 

  45. Oh Y, Muller HL, Lamson G, Rosenfeld RG: Insulinlike growth factor (IGF)-independent action of IOF-binding protein-3 in Hs578T human breast cancer cells. J Biol Chem 268: 14964–14971, 1993

    Google Scholar 

  46. Oh Y, Muller HL, Pham HM, Rosenfeld RG: Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268: 26045–26048, 1993

    Google Scholar 

  47. Lalou C, Lassarre C, Binoux M: A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-1 and insulin. Endocrinology137: 3206–3212, 1996

    Google Scholar 

  48. Oh Y, Nagalla SN, Yamanaka Y, Kim H, Wilson L, Rosenfeld RG: Identification and characterization of insulin-like growth factor binding protein (IGFBP)-7: Recombinant human mac25 protein specially binds IGF-I and IGF-II. J Biol Chem 271: 30322–30325, 1996

    Google Scholar 

  49. Wilson EM, Oh Y, Rosenfeld RO: Generation and characterization of an IGFBP-7 antibody: identification of 31-kDa IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J Clin Endocrinol Metab 82: 1301–1303, 1997

    Google Scholar 

  50. Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D: Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and oestrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 157: 229–236, 1993

    Google Scholar 

  51. Yee D, Jackson JG, Kozelsky TW, Figueroa JA: Insulin-like growth factor binding protein 1 expression inhibits insulinlike growth factor I action in MCF-7 breast cancer cells. Cell Growth Differ 5: 73–77, 1994

    Google Scholar 

  52. Van Den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB, Yee D: Polyethylene glycol conjugated insulinlike growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mouse. Eur J Cancer 33: 1108–1113, 1997

    Google Scholar 

  53. Toner E, Barber MC, Travers MT, Logan A, Flint DJ: Hormonal control of insulin-like growth factor-binding protein 5 production in the involuting mammary gland of the rat. Endocrinology 138: 5101–5107, 1997

    Google Scholar 

  54. Kjellen L and Lindahi U: Proteogltcans: structure and interactions. Annu Rev Biochem 60: 443–475, 1991

    Google Scholar 

  55. Rudland PS, Barraclough R, Fernig DG, Smith JA: Mammary stem cells in normal development and cancer. In: Potton C (ed) Stem Cells and Cancer. Churchill Livingstone, London, 1996, pp 147–232

    Google Scholar 

  56. Iozzo RV: Proteoglycans and neoplasia. Cancer Metast Res 7: 39–50, 1988

    Google Scholar 

  57. Delehedde M, Deudon E, Boilly B, Hondermarck H: Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity. Exp Cell Res 229: 398–406, 1996

    Google Scholar 

  58. Zhou FY, Owens RT, Hermoenen J, Hook M: Is the sensitivity of cells for FGF-1 and FGF-2 regulated by cell surface heparan sulfate proteoglycans? Eur Cell Biol 73: 166–174, 1996

    Google Scholar 

  59. Lambrecht V, Le Bourhis X, Toillon RA, Boilly B, Hondermarck H: Alterations in both heparan sulfate proteoglycans and mitogenic activity of fibroblast growth factor-2 are triggered by inhibitors of proliferation in normal and breast cancer epithelial cells. Exp Cell Res 245: 239–244, 1998

    Google Scholar 

  60. Rahmoune H, Rudland PS, Gallagher JT, Fernig DG: Hepatocyte growth factor/scatter factor has distinct classes of binding site in heparan sulfate from mammary cells. Biochemistry 37: 6003–6008, 1998

    Google Scholar 

  61. Ervin PR, Kaminsky JMS, Cody RL, Wicha MS: Production of mammastatin, a tissue-specific growth inhibitor, by normal human mammary cells. Science 244: 1585–1587, 1989

    Google Scholar 

  62. Masson PL, Heremans JF, Schonne E: Lactoferrin an iron binding protein in neutrophilic leukocytes. J Exp Med 130: 643–658, 1969

    Google Scholar 

  63. Damiens E, Mazurier J, El Yazidi I, Masson M, Duthille I, Spik G, Boilly-Marer Y: Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumor cells. Biochim Biophys Acta 1402: 277–287, 1998

    Google Scholar 

  64. Damiens E, El Yazidi I, Mazurier J, Duthille I, Spik G, Boilly-Marer Y: Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem 74: 486–498, 1999

    Google Scholar 

  65. Lai LC, Kadory S, Siraj AK, Lennard TW: Oncostatin M, interleukin 2, interleukin 6 and interleukin 8 in breast cyst fluid. Int J Cancer 59: 369–372, 1994

    Google Scholar 

  66. Liu J, Spence MJ, Wallace PM, Forcier K, Hellstrom I, Vestal RE: Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. Cell Growth Differ 8: 667–676, 1997

    Google Scholar 

  67. Liu J, Hadjokas N, Mosley B, Estrov Z, SpenceMJ, Vestal RE: Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine 10: 295–302, 1998

    Google Scholar 

  68. Huynh H, Pollak M: Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens. Clin Cancer Res 3: 2151–2156, 1997

    Google Scholar 

  69. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that TGFb is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417–428, 1987

    Google Scholar 

  70. Pratt SE, Pollak MN: Insulin-like growth factor binding protein 3 (IGFBP-3) inhibits estrogen stimulated breast cancer cell proliferation. Biochem Biophy Res Commun 198: 292–297, 1994

    Google Scholar 

  71. Huynh H, Yang X, Pollak M: Estradiol and anti-estrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loup in human breast cancer cells. J Biol Chem 271: 1016–1021, 1996

    Google Scholar 

  72. Gucev ZS, Kelley KM, Rosenfeld RG, Oh Y: Insulin-like growth factor binding protein-3 (IGFBP-3) mediates retinoicacid (RA)-and transforming growth factor-b2 (TGF-b2)-induced growth inhibition in human breast cancer cells. Cancer Res 56: 1545–1550, 1996

    Google Scholar 

  73. Swisshelm K, Ryan K, Tsuchiya K, Sager R: Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci USA 92: 4472–4476, 1995

    Google Scholar 

  74. Kurtz A, Vogel F, Funa K, Heldin CH, Grosse R: Developmental regulation of mammary-derived growth inhibitor expression in bovine mammary tissue. J Cell Biol 110: 1779–1789, 1990

    Google Scholar 

  75. Wallach D, Kovalenko AV, Varfolomeev EE, Boldin MP: Death-inducing funtions of ligands of the tumor necrosis factor familly: a Sanhedrin verdict. Curr Opinion Immunol 10: 279–288, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bourhis, X.L., Toillon, RA., Boilly, B. et al. Autocrine and paracrine growth inhibitors of breast cancer cells. Breast Cancer Res Treat 60, 251–258 (2000). https://doi.org/10.1023/A:1006461621905

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006461621905

Navigation